Navigation Links
Recall of Anemia Drug Omontys Rings Alarm Over Biosimilars
Date:2/27/2013

ATLANTA, Feb. 27, 2013 /PRNewswire-USNewswire/ -- Makers of innovative biologics have legitimate reason to sound alarms about automatic substitution of biosimilars that have not proven their interchangeability – and it's not just because of the potential impact to their bottom line. That point was driven home by the recent recall of Affymax Inc. and Takeda Pharmaceutical Co. Ltd.'s anemia drug Omontys (peginesatide), according to BioWorld.

(Logo: http://photos.prnewswire.com/prnh/20120628/DC32901LOGO)

Though Omontys is not a biosimilar, the unexpected postmarketing reports of serious hypersensitivity reactions (three patient deaths) linked to the erythropoiesis-stimulating agent (ESA) served as a reminder of the variability of biologics, their sensitivity to minute manufacturing changes and the difficulty of catching a rare safety signal in the full-blown biologic development process – let alone an abbreviated biosimilar path, as noted in a blog post by BioWorld Washington Editor Mari Serebrov

This should give the FDA pause about its approach to biosimilar approval. Because of the variability of biologics, biotechs and patient advocacy groups have urged the agency to require safety data for biosimilars. While the FDA maintains that patient safety is its primary concern with any drug, it insists that since the reference biologic has demonstrated safety and efficacy, all a biosimilar must do is demonstrate similarity to the reference drug. The goal is not to require redundant clinical trials that would be expensive, unnecessary and unethical.

Neither the FDA nor most biotechs want the biosimilar path to fail. But they understand the complexities of making biologics, and they know that one disaster now could doom or indefinitely delay the new approval path.

Unfortunately, people unfamiliar with the differences between biologics and small molecule drugs, which are far less complex than biologics, too often equate biosimilars with generics. Since generics are unquestionably accepted as equivalent to small molecule reference drugs, they can be substituted automatically for the brand drug at the pharmacy. Yet even generics have had equivalency problems.

Editor's note: This is an excerpt from a BioWorld Perspectives Blog post. Read the complete post: http://bioworld.blogs.bioworld.com/.

BioWorld ‑ the industry's most trusted news service focused on the development of biologics for more than two decades ‑ has identified and profiled 139 key biosimilar developers with >276 biosimilars in their pipelines, according to The Biosimilars Game: A Scorecard for Opportunities, Threats and Critical Strategies, a new report by BioWorld Data. Call for details (800) 477-6307.

Contact: Lynn Yoffee
404-262-5408
www.bioworld.com


'/>"/>
SOURCE BioWorld
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Rust Gets Toyota Recalling Its Tacoma; Hub on Wheels Advises Car Owners to Deal With Any Other Car Rust Problem with Rusterizer
2. Zamansky & Associates LLC Investigates Affymax Inc. Over Its Recall of Omontys Due to Fatal Reactions
3. A mouse model brings new perspectives on Lafora disease
4. At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
5. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
6. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
7. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
8. ScaleMatrix Leads the Way Unveiling the Industry’s First Transparent Pricing Tool in Private Cloud Offerings
9. Finding Brings Scientists One Step Closer To Parkinsons Drug
10. Rusterizer Brings Out New Non-Toxic Rust Remover, Gives Samples of the Product
11. Elsevier Expands Access to Digital Offerings Through Collaboration with Follett
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... ... Bacterial biofilms, surface adherent communities of bacteria that are encased in a ... and catheter infections to gum disease and the rejection of medical implants. Though ... year, there is currently a paucity of means for preventing their formation or treating ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... it is exhibiting in booth B2 at the Association for Pathology Informatics ... , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. ... 2017 at the Prince Of Wales Private Hospital. The procedure was performed on ... The patient failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic ...
(Date:5/18/2017)... Massachusetts (PRWEB) , ... May 17, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released version 9.0 ... of work into this latest version of Cockpit,” says David Cronin, CEO of ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):